SCHEMBL3920283

SCHEMBL3920283

O=[N+]([O-])c1ccc(C(O)c2ccnn2COCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
MYC P01106 1/20 0.40
MAX P61244 1/20 0.40
CYP11B1 P15538 4/20 0.39
CYP11B2 P19099 4/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP19A1 P11511 2/20 0.38
PIN1 Q13526 2/20 0.38
CTSV O60911 2/20 0.37
CTSL P07711 2/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
ABCB1 P08183 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915526 0.83 MYC (0.36) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL3927192 0.76 ALOX5 (0.48) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL6373712 0.73 MYC (0.50) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL6373720 0.73 MYC (0.50) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL6592493 0.71 MYC (0.53) POLBMYCMAXSENP8SENP7
SCHEMBL8177835 0.71 MYC (0.48) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL6592919 0.71 MYC (0.50) POLBMYCMAXSENP8SENP7
SCHEMBL1040246 0.70 CTSV (0.51) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL30184780 0.70 CTSV (0.51) POLBMYCMAXCYP11B1CYP11B2
SCHEMBL6373099 0.70 MYC (0.52) MYCMAXCYP19A1CTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
CN-101421256-A Thiadiazolidinone inhibitors of ptpase NOVARTIS AG (CH) 2009-04-29 CN disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC POLB 2399/4885MYC 1166/4885MAX 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.